Over the last three months, 8 analysts have provided diverse opinions on Teva Pharmaceutical Industries (NYSE:TEVA), with recent ratings ranging from bullish to bearish. The average 12-month price target for TEVA has been raised to $14.25, marking a 24.67% increase from the previous average of $11.43. Analysts from firms including Piper Sandler, Goldman Sachs, Barclays, Jefferies, HSBC, and UBS have adjusted their ratings and price targets, reflecting a generally positive outlook on the company. Teva, a leading generic drug manufacturer, has shown a positive revenue trend with a growth rate of 15.77% as of December 31, 2023, and has outperformed in net margin and ROE, despite a high debt-to-equity ratio.